Cresset Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.4M Buy
260,937
+1,540
+0.6% +$105K 0.07% 158
2026
Q1
$16.8M Buy
259,397
+36,682
+16% +$2.59M 0.07% 180
2025
Q4
$15M Sell
222,715
-935
-0.4% -$62.9K 0.06% 191
2025
Q3
$16.4M Sell
223,650
-66,007
-23% -$4.38M 0.07% 164
2025
Q2
$15.1M Sell
289,657
-16,714
-5% -$951K 0.07% 161
2025
Q1
$19.5M Sell
306,371
-26,963
-8% -$1.57M 0.1% 130
2024
Q4
$15.9M Sell
333,334
-779
-0.2% -$39.9K 0.08% 159
2024
Q3
$19.1M Buy
334,113
+43,890
+15% +$2.52M 0.07% 174
2024
Q2
$15.2M Buy
290,223
+9,472
+3% +$415K 0.06% 200
2024
Q1
$11.4M Buy
280,751
+72,853
+35% +$2.73M 0.06% 225
2023
Q4
$7.68M Buy
207,898
+27,911
+16% +$1.05M 0.05% 256
2023
Q3
$6.88M Buy
179,987
+74,439
+71% +$3.05M 0.03% 267
2023
Q2
$3.81M Buy
+105,548
New +$3.6M ﹤0.01% 477

Other funds holding HALO

Cresset Asset Management's HALO Position: Q2 2026 in Review

Cresset Asset Management increased its Halozyme (HALO) stake by 0.59% in Q2 2026, buying an estimated $105K and bringing the position to 260,937 shares worth $20.4M. The position accounts for 0.07% of the portfolio, ranked #158.

Cresset Asset Management first reported a position in HALO in Q2 2023 and has held it in 13 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Cresset Asset Management held 260,937 shares of Halozyme worth $20.4M as of Q2 2026.
  • Cresset Asset Management bought 1,540 Halozyme shares in Q2 2026, an estimated $105K.
  • Halozyme made up 0.07% of Cresset Asset Management's portfolio in Q2 2026, its #158 holding.
  • Cresset Asset Management first reported a position in Halozyme in Q2 2023 and has held it in 13 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.